Member Info for JustHereForHemo

Well said HH, I have actually avoided posting thus far to let a post from Haywain stay on page 1 as much as possible because it is so well written, raw and put in words much better than I can how I feel about shorting. On that subject in particular which has had alot of focus recently in my opinion, shorting here is just wrong, its not betting that Hemogenyx will fail its purely betting that Hemogenyx will need to raise funds via a placing and hoping to make it more expensive for the company by shorting. Having said that, I believe they have made a mistake and short shares MUST be bough back and I see that as a huge opportunity as the sheer scale means the SP will be pushed higher whenever these positions are closed.

I agree 100% that focus has been completely shifted away from the science and what the company HAS achieved and what happens next and been totally hijacked by wall to wall coverage of shorting and funding which is just bonkers and helps nobody but those who want focus distracted from the good work. The reality is Hemogenyx today is Clinical and Vlad has options, I have made my opinion clear, I could be wrong but IMO next news is launch of clinical trials, they had hoped to launch in 2023 but delays.... The key there is that they said that in September, giving themselves only 3 months including having CH lifted etc so they clearly did not anticipate a long delay between lifting CH and launching the trial, a few weeks at most. So next week I anticipate an update on HEMO-CAR-T trials and I fully expect to come with it some sort of funding arrangement which will put everybody at ease.

Worth remembering also that we have recently had some fantastic news on CBR and as is clear from the past few weeks updates have started to flow as Vlad has been released from dedicating so much time to getting CAR-T clinical. That work is done, they will announce trials and the doctors and Prevail etc will take over. It is staggering and amazing that the SP is still here, Hemogenyx is an absolute outlier in this field right now, but markets correct and adjust. Good luck to all shareholders who are supporting an amazing company hoping to save lives in the very near future!

Final note, please take the time to read the post last night from Haywain, it was excellent!

Stu, I am categorically stating I believe you are wrong, but the fact remains even if in some parallel universe you were right that would mean you have dedicated hours upon hours to try and convince people to sell with the single goal of dropping the share price so any placing would be lower and the company could raise less money to spend on research and clinical trials. Have you any idea how empty your soul must be to get joy out of that?

I know your just guessing, and I'm confident your wrong, but seriously? None of that seems off or wrong to you?

Pumpkin ofcourse 20mil is not the cause of the entire drop! Nobody said it was, if the ONLY people selling were the shorters then it would be impossible for them to make money. They need people to panic sell for them to make money.

Stu, err no. Like I have stated my belief is hemo will announce a funding package along side the start of trials. It's literally on the prevail website, they invest and fund clinical trials!

I can have noodles AND rice with my dinner, the presence of the rice does not some how change the fact there is noodles on my plate.

Of course mint was damaging, they did alot of forward selling/shorting. When I found out who was connected I spent alot of time lobbying vlad to get rid and managed to recruit alot of people to take part in the placement to repay the CLNs.

Why would I not acknowledge that? If you forget our past your doomed to repeat.

The other even bigger mistake they made was much earlier than Mint was the investors they chose for the initial RTO.

Does not mean that suddenly shorters get a free pass to attack a company trying to save lives without criticism. It's wrong and you know it.

Stu has answered, nothing makes it special, the key in his answer was "Financial resources at hand" and THIS is where we agree. The risk to Hemogenyx, and its not really a risk but more of an impediment, is the lack of significant "Financial resources at hand" due in no small part to the low mCap which is due in no small part to the shorting and trading. If the company had a considerably higher mCap it would be much harder to short and attack, this would make it easier to raise funds when needed and would in turn lead to a higher and safer valuation. Which basically means your arguing FOR the very argument I am making! Which just re-enforces that your not that stupid, you just want to create just enough noise to put some people off to get your trade away. So basically your just trying to waste my time to fill this board with useless noise and detract from the fact that 2 weeks ago Hemogenyx got their Clinical Hold lifted by the FDA and are now CLINICAL and allowed to start Clinical trials with HEMO-CAR-T.

GO HEMO! :-)

If its all really simple Stu then perhaps you could educate us?

What makes Hemogenyx special?

Why is Hemogenyx the outlier? Why is EVERY other company with CAR-T in clinical trials significantly higher than us? What is so special about hemogenyx that the risk here is so much higher than EVERY other pharma company out there doing CAR-T? AND there are companies also targeting AML, they dont seem to have the same issues with valuation.

The difference?

Hemogenyx is higher risk BECAUSE ITS SO CHEAP. The lower mCap makes it harder and more damaging to raise funds via placings and makes it MUCH easier to manipulate by fewer people and less resources. You know the biggest risk to Hemogenyx is the low mCap, your not an idiot, you also know its that low mCap and low volumes and low visibility which make it so attractive to you and others who short and trade here. It is just not cool that you have picked a company that literally wants to save lives when there are much better targets out there that do nothing but fleece shareholders and their activities directly or indirectly cause cancer!

Err Truffle, there is PLENTY wrong with shorting, its acceptable for providing liquidity in a market where people want to buy and there is just no stock. Or in a company where they have been exposed to be a fraud or criminal enterprise of some sort. Or where some sort of pump and dump scheme being orchestrated by directors etc. There are cases where it is appropriate.

HOWEVER all we see these days is traders either knowing or just suspecting a placing in a small cap short sell as hard and as much as possible in an attempt to force the SP down, then following up with trolling posts. The intent to make the SP as low as possible incase there is a placing to maximise their profits. The issue? This DOES hurt the company, it makes it very hard to raise any sizeable amount of money, there is a limit to how many shares can be issued.

With Hemogenyx it has happened so much and so many times that Vlad has had to curtail research over the years, reduce the work to keep within what he could afford. At this point Hemogenyx could well have been in clinical trials for CAR-T and CBR by now if money had been no issue, lives COULD have been saved already.

Shorting 100% has a direct negative impact on the company and it is NOT a legitimate form of trading as all too often its associated with market manipulation, abuse and insider trading.

Hemogenyx was at 7p when the news landed on FDA approval, between shorting AND traders selling the SP is now back at 3p. At 7p the company would have had no issue whatsoever raising 10m or so to fund CBR research at 6p and nobody would have complained, now? they will probably have to wait a while to raise and settle for moving CAR-T along. Shorting Hemogenyx is out of control, disgusting and the delays will cost lives, if not done so already.

Yes, IG last report was 80-90mil shares on their site, I use IG alot and have added and know others who have also bought who use IG so honestly IMO they have more, but I am not paying 100 quid to get the updated register.... 11% of share positions by clients on IG ONLY, so we are talking somewhere in the 8-10mil range for IG. IB last BIG chunk was like 12mil borrowed back when the FDA lifted the hold, other smaller borrowings before and after but again, some closing and I cba to work out exact positions. Bottom line is I have 3 broker accounts and 2 of them allow shorting in Hemogenyx so its not exactly a stretch to assume many others do also. So that 20m figure being quoted as short is probably quite conservative, it is impossible to know the exact total.

IG....err.... perhaps you are in need of corrective glasses :P OF COURSE you can short Hemogenyx!

This is literally a copy and paste from the IG website: "11% have short positions"

on IB its a chart showing numbers borrowed so you have to do your own maths. There are others but I cba to register for them all.

Truffle, register as professional and you can do alot more.... Quite often though you have to ring up, spreadex will let you short but you must ring up. But at this point there is no real debate, IG, IB etc display the short interest on their sites, so its a guesstimate as to the total size of current shorts as IG for example only give percentages,( Currently 11%) but 20m seems conservative.

They can use whatever size they want? I just gave an example of 100k. And to be honest if its spread bet it wont print like that anyway, they try and close positions with IG or IB or II or whoever and that broker lets them close xyz amount and then they will do a consolidation and balancing trade if required to reduce their exposure which could be 500k in an after hours trade print. What I am saying is, yes its entirely possible to close in small steps, and if they have a really good broker they can possibly get out with decent profit before the SP moves much. 20m is alot though, but I assume there is more than one person shorting here, so first mover advantage and all that...

Individuals have shorted Hemogenyx, not a company, but yes, if they start buying small blocks, 100k or so they could start closing without moving the SP too much, but with that much stock short it would take a long time. But like I said to Stu before, if he manages it down here? He will have made profit and won, at the expense of a company looking to cure people with cancer, so good luck.....

I do not for one second believe that any CEO ever "give shorters a chance", if that ever were the case then any shorter who was "let out" would bookmark that company as a favourite for all future shorting!

A CEO COULD directly go after the shorts, by releasing news, director buys, share buy back, PR rampage etc, attract enough buying and shorters get closed out. Some times there has been so much damage to a companies valuation that the CEO has no other choice but to confront the shorting face on.

If Vlad is organising the funding as part of the offical Prevail launch of clinical trials as seems likely then its not a case that Vlad is giving shorters a chance, it simply takes a bit of time. A placing can and has been done in the space of a few hours, if he wanted to do one on the day the Clinical Hold was lifted? He easily could have, the interest generated would have made it significantly oversubscribed. The fact we are now almost 2 weeks since hold was lifted just makes it more the likely that the funding will be linked to trials which is exactly what we want, despite what our resident trolls would like as they continue to attack a company working hard to save lives.

MJ, I know you asked someone else, but think any one of us can answer that.

Hemogenyx are CLINICAL, they have a 100% owned CAR-T treatment for AML approved to start clinical trials.

They also have CBR(Can potentially target all viruses) and CDX. The current mCap of Hemogenyx is around £30mil.

There are no other CLINICAL pharma with CAR-T in this space even remotely close to this low an mCap.

Companies with CAR-T are 100-300m+ many are worth billions. Licencing deals are often in the 500m+ inc milestones range for CAR-T even at early stages.

So the valuation RIGHT now is wrong, 3p IS WRONG.

The valuation of a company is based on the share price times number of shares in issue, but right now? the number of shares that have been sold is much greater than the free float. The short position is huge right now, and short shares are borrowed, they have to be returned which means buying back, which pushes the SP up.

The shorters started after FDA approval, they carried on expecting some huge placing which still has not materialised. Starting trials, news of investment from Prevail or some other arrangement etc, all of these will force the shorts to close. Depending on how good the news is will decide what price the shorts close at, its a Mexican standoff at present, the shorters vs Vlad. But its Vlad who is calling the shots. That said 6p is VERY realistic, the short position is so large they cannot possibly close without pushing the SP up considerably.

I agree pingu, my 2 cents?

The usual crew will have been on the phone to peterhouse by now signing up for the expected placing. Peterhouse will have been onto Vlad offering a few mill at what? 2.5p? No interest? OK 3p? But things have changed... Vlad is not forced to go begging any more, Hemo are clinical and Prevail have deep pockets. Go short, hurt the SP then dangle a consolidation prize of a few mill significantly discounted from when you started shorting and expect him to say thank you while you Roger him with no lube. But I'm gonna bet this time Vlad said no 😉

Tick tock.....

Oops 😬 did I hit too close to home?

Simples, IF your able to close and buy back in the 3-3.5p range YOU win, feel good about attacking a company aiming to cure cancer.

If you're not able to close before the Prevail RNS lands? We win.

Simples.

Don't be in such a bad mood, and you never asked me that? The answer is fairly obvious though so if you need me to answer there is something wrong.... shorts opened after FDA approval, sp fell hard, no further explanation or justification needed for that, Good RNS, short, simple. But then 2 further RNSs attracted more buying, stopped the fall and put more pressure on shorters and traders. If these genius shorters knew about some so far unmateralised massive discount placing then they would also know about those 2 RNSs... they did not.

The fact is it DOES NOT MATTER if Vlad did a placing or not to the shorters, the fear of some massive diluting placing is all they need, scare people into selling and you win.

But here's the catch... if shorters successfully push the sp down bur people DONT sell and volume dries up like we have seen? Its incredibly difficult to close out shorts or buy back in. If the shorters pushed the SP down here with 20mil shares then buying 20m pushes it right the way back up again, same way I couldn't sell my shares now in one day without hurting the sp.

Maybe if the shorters had not gotten greedy and pushed the sp down so far Vlad might have done a placing at 6p as previously predicted, but now? Vlad has options, it IS a stand off between Vlad and the shorts. But volume is too low for shorts to close and Vlad is in the driving seat so looking forward to what happens next! If shorts had managed to close down here near 3p they would have won, but with 3m total volume??? Nope ain't happening and chances of a prevail update any day grows, shorts are trapped and I'm here to enjoy every minute of it.

Tick tock!!!

Please stop HT.... I'm starting to like you and it makes me uncomfortable......

The share register is mostly filled with trustee account holders, by and large not much use.